
Shares of Heartbeam Inc (NASDAQ:BEAT) rose sharply in pre-market trading after announcing its regulatory strategy following the Food and Drug Administration’s Not Substantially Equivalent (NSE) decision on its 12-lead Electrocardiogram Synthesis Software.
The Santa Clara-based medical technology company is pursuing multiple options, including an appeal process or a 510(k) resubmission, a premarket FDA filing showing the device is equivalent to legally marketed products.